Lung Cancer—Molecular Insights and Targeted Therapies (Volume II)

Dear Colleagues,

This Special Issue is the second edition of the Special Issue Lung Cancer—Molecular Insights and Targeted Therapies https://www.mdpi.com/journal/cancers/special_issues/LCMITT.

Lung cancer is the leading cause of cancer-related death worldwide, with a 5-year survival rate of approximately 18%. Each year, more than 2 million people are diagnosed with lung cancer around the world, and most of them are diagnosed with locally advanced or metastatic disease. Therefore, early diagnosis is one of the key steps to improve and promote precision medicine for this disease. 

Lung cancer management has changed in the last decade. State-of-the-art molecular pathology has allowed the development of more effective therapeutic strategies for this disease. However, there is still a long way to go before precision medicine is available for all, which will require further research into the molecular mechanisms underlying lung cancer and potential new druggable targets based on the molecular background of tumors. The current issue aims to increase our knowledge in order to achieve these goals.

We are pleased to invite both original research and review articles that highlight recent advances in this exciting field of research. We are looking for articles on the discovery of molecular insights and targeted therapies for use in preclinical in vitro and in vivo models and/or articles investigating their role in translation to clinical practice. We also welcome articles that cover other topics with the aim of improving or providing an alternative paradigm of precision medicine in lung cancer.

I look forward to receiving your contributions.

Dr. Sonia Molina-Pinelo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.